Our research aims at understanding the mechanisms of action of novel biological pharmaceuticals on tumor cells.
We are focusing on extra- and intracellularly functional antibodies, and fragments to tailor the antibody-target interaction, as well as to widen the druggable proteome for antibody therapeutics.
We also aim at developing new drug delivery technologies to target tumors that for one reason or another are difficult to reach by drugs because of, for example, low exposure levels, metabolism, or adverse toxicity.
A third research interest concerns a novel proteomics methodology for characterization of membrane proteins aimed at epitope discovery for antibody therapeutics targeting ion channels, and GPCRs.
|Alexandra Andersson||Forskningsassistent, UF|
|Felicia Jennysdotter Olofsgård||Anknuten|
|Oscar Jungholm||Doktorand, Forskarstuderande|
|Monica Marcus||Senior lab manager|
|Åsa Konradsson Geuken||Associated|
- Oblique Therapeutics AB